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Abstract: The binding between the HIV-1 trans-activator of transcription (Tat) and 
p300/(CREB-binding protein)-associated factor (PCAF) bromodomain is a crucial step in 
the HIV-1 life cycle. However, the structure of the full length acetylated Tat bound to 
PCAF has not been yet determined experimentally. Acetylation of Tat residues can play a 
critical role in enhancing HIV-1 transcriptional activation. Here, we have combined a fully 
flexible protein-protein docking approach with molecular dynamics simulations  
to predict the structural determinants of the complex for the common HIV-1BRU  
variant. This model reproduces all the crucial contacts between the Tat peptide 
46SYGR(AcK)KRRQRC56 and the PCAF bromodomain previously reported by NMR 
spectroscopy. Additionally, inclusion of the entire Tat protein results in additional contact 
points at the protein-protein interface. The model is consistent with the available 
experimental data reported and adds novel information to our previous structural 
predictions of the PCAF bromodomain in complex with the rare HIVZ2 variant, which was 
obtained with a less accurate computational method. This improved characterization of 
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Tat.PCAF bromodomain binding may help in defining the structural determinants of other 
protein interactions involving lysine acetylation.  
Keywords: Tat; PCAF BRD; HIV-1; docking; protein-protein interaction 
 
1. Introduction 
The development of drugs against human immunodeficiency virus type 1 (HIV-1) was initiated 
about 30 years ago [1]. Since then, there have been 30 available antiretroviral drugs approved by the 
U.S. Food and Drug Administration (FDA). Current therapies against the AIDS pandemic are mainly 
based on inhibition of the three enzymes expressed by HIV-1 (protease, reverse transcriptase and 
integrase) [2±5]. Unfortunately, all of these approaches suffer from drug resistance due to the emergence 
of viral mutants [6]. In a rapid process of Darwinian evolution, the virus has developed functional 
enzyme variants not inhibited by current therapies/drugs. Several promising new strategies may, at 
least in part, counteract such viral hypervariability [7,8]. One of these strategies interferes with the 
HIV-1 transcriptional activity induced by the HIV-1 trans-activator of transcription (Tat) protein [9±11] 
(Figure 1a). Tat is a small and flexible protein, which acts as a molecular adaptor. Nuclear magnetic 
resonance (NMR) experiments reveal no secondary structure elements for free Tat in solution [12±16], 
although dramatic structural changes have been observed (both X-ray and NMR structures) when the 
protein is in complex with host cell partners [17,18]. The high plasticity of Tat is demonstrated by the 
fact that it can tolerate up to a 40% of sequence variation without loss of activity [19].  
Post-translational modifications²in particular acetylation of Tat residues can play a critical role in 
HIV replication, enhancing HIV-1 transcriptional activation [20±22].  
Tat is acetylated at K50 by the p300/CPB co-activator and histone acetyltransferase  
(HAT) [10,11,21,23±25]. The p300/CPB protein contains several functional modules, including a 
nuclear receptor interaction domain (RID), a CREB and MYB interaction domain (KIX), 
cysteine/histidine regions (TAZ1/CH1 and TAZ2/CH3), an interferon response binding domain 
(IBiD), a histone acetyltransferase (PAT/HAT) domain [20,26±29], and a motif called the 
bromodomain (BRD). BRDs have recently been discovered to function as acetyl-lysine binding 
domains [30]. They feature a characteristic left-handed, four-helix bundle (helices Į= Į$ Į% and Į& 
(Figure 1b). A large loop links helices Į= and Į$ (ZA loop), and a shorter loop links helices Į% and 
Į& (BC loop) [23]. Acetylated lysines bind between both loops by inserting the acetyl moiety along 
the longitudinal axis of the helices and between the four helices bundle [23,25,30]. In all the structures 
of BRDs in complex with cognate histone peptides so far determined [31], the acetyl moiety forms a 
hydrogen bond with a very conserved asparagine residue at the end of the cavity, serving as an anchor 
and providing specificity for acetylated versus non acetylated lysines [32]. Additional contacts with 
flanking amino acids in the target motif determine specificity/affinity for the large variety of BRD 
modules so far reported [31]. It is worth noticing that the binding regions belong to post-transcriptional 
modified histone tails, which are intrinsically disordered [33±35]. Therefore, it is not clear whether 
additional contacts may contribute to the recognition process.  
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Figure 1. Molecular representation of Tat.PCAF model and interactions. (a) HIV-1 Tat 
protein. The Tat protein lacks secondary structure elements [13]. Tat consists of six 
regions: Region I (in red) includes a proline-rich tract. It plays an important role in the 
entry of Tat into the cell [36]. Region II (in yellow) includes a cystein-rich tract. It is 
important for the transactivation ability of Tat [37]. Region III (in green) includes the motif 
RKGLGI. It is considered as the hydrophobic core of the protein and is conserved across 
HIV-1, HIV-2, and SIV Tat [38]. It does not have any known specific function [38]. 
Region IV (in orange) contains the basic domain (49RKKRRQRR56), arginine-rich motif, 
conserved across Tat proteins [39,40]. This region is required for binding to the viral RNA 
TAR (trans-activating response region) [41±45], as well as a variety of proteins, including 
PCAF BRD [18]. Region V (in violet) is a glutamine-rich region [46]. It is involved in 
microtubule polymerization and Tat-mediated apoptosis of T-cells [46]. Region VI  
(in blue, amino acid 73 to 86 or 101, depending on the virus strain) [10,11] includes the 
RGD motif that mediates Tat binding to cell surface integrins [47]. It is involved in cell 
adhesion [48]; (b) PCAF BRD. Cartoon representation of PCAF BRD NMR structure 
(PDBID 1JM4 [18]). It has a four-helix bundle (helices Į= Į$ Į% and Į&; (c) 7DW¶V core 
domain and arginine-rich motif (ARM) interacting with PCAF BRD NMR structure [18]. 
PCAF BRD (orange) is represented in cartoon and traced with the residues in contact with 
Tat (green) in orange stick forms. Tat is represented in stick forms with oxygen and 
nitrogen atoms of AcK50 in red and blue, respectively. 
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Tat is also acetylated at K28 by the p300/CBP-associated factor (PCAF), thereby enhancing  
Tat binding to the protein P-TEFb [17]. This may in turn regulate functionally critical steps in  
transcription [20±22,49±51]. PCAF is a 90-kDa protein that contains the P300/SRC-1 domain 
(residues 1 to 352), the HAT domain (residues 518 to 649), which acetylates K28 [18,51] and a  
C-terminal BRD (residues 719±832) [18]. The BRD binds to the Tat protein, which is acetylated at 
lysine 50 (AcK50). Despite the fact that the structural determinants of full-length PCAF in complex 
with Tat have not yet been determined experimentally, the NMR structure of the complex between an 
acetylated Tat peptide (46SYGR(AcK)KRRQRC56) (Figure 1c) and the PCAF BRD has been solved by 
NMR spectroscopy [18]. 
The structural determinants of the full-length Tat PCAF BRD complex were predicted based on 
molecular dynamics simulations, combined with biochemical and FRET experiments [52]. This model 
was built using the structure of the isolated Z2 variant of the HIV-1 Tat [15]. In contrast to the existing 
structures of BRDs in complex with histone peptides, that model pointed to the presence of contacts 
between the BRD and non-adjacent regions of the acetylated partner. Furthermore, Tat Regions III and 
IV made extensive contacts with the ZA loop of the PCAF BRD (Figure 1). Although these contacts 
were not present in the NMR structure, which only contained a Tat peptide, they were experimentally 
validated [52], supporting the idea that significant changes in the protein-protein interface may take 
place in the presence of the entire Tat molecule.  
Here we construct an updated structural model of the Tat PCAF BRD complex using a more 
accurate docking procedure. This is the fully flexible protein-protein technique as implemented in the 
data-driven docking program HADDOCK version 2.1 [53,54] followed by molecular dynamics (MD) 
simulations. Importantly, we focused on the 86 amino acids Tat BRU variant, PDBID 1JFW [13], a 
representative of HIV-1 subtype B. This variant is actually the more common HIV subtype in Europe 
and North America [12]. The Z2 variant of the protein used in our previous study is evolutionally 
closer to early strains of the virus, but is nowadays much less abundant [12]. Docking studies 
involving Tat and its cellular partners can be expected to be feasible. Indeed, (i) HADDOCK (High 
Ambiguity Driven protein-protein DOCKing) [53,54] has been used to predict the protein-protein and 
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protein-nucleic acid complexes based on available experimental data [55±57]; (ii) HADDOCK has 
also been applied to intrinsically disordered proteins for which NMR structural information is available, 
such as Tat [50±53]; (iii) HADDOCK has been successfully applied to a variety of NMR structures 
with a low number of 12(¶V per atom [54,55], similar to the ones we found in the available Tat NMR 
structures. Moreover, HADDOCK complemented by MD also provides reasonable results in those 
cases where the protein undergoes conformational changes [56±58]. Therefore by using the docking 
procedure combined with the MD simulations, we believe that a reasonable model of Tat can be assured. 
2. Results and Discussion  
2.1. Intermolecular Contacts 
In our full-length Tat.PCAF BRD model, the interface between the BRU Tat and PCAF BRD 
complex (BRU Tat.PCAF hereafter) consists of Tat residues 47±55 and PCAF BRD residues 722±781. 
We focus on the contacts at the protein/protein interface. We first describe the hydrophobic contacts 
(HCs). Then we move our attention to intermolecular hydrogen bonds (HBs) and salt-bridges (SBs). 
The residues belonging to PCAF BRD are indicated in the following text with italics, while those of 
Tat with normal text. 
AcK50 forms HCs with F748, V752, K753, Y760, I764, N798, Y802 and Y809 (Table 1 and 
Figure 2a). These results are in agreement with in vitro mutagenesis experiments in which the mutants 
to alanine of these PCAF residues strongly dismissed the Tat.PCAF BRD binding [18]. The role of 
Y760 in binding has been confirmed also in vivo by fluorescence resonance energy transfer (FRET) 
experiments of full-length acetylated Tat with PCAF BRD [52]. The mutant Y760D indeed impaired 
Tat binding to PCAF BRD (Table 1) [52]. Q54 establishes HCs with PCAF E756. Both residues are 
located at the edge of a hydrophobic cavity of Tat (Figure 2b).  
R49 forms HCs with P747, E750; K51 with E750, V752, K753; R52 with K753, E756 (Figure 2a); 
and Y47 with P804, S807, E808 and Y809 (Figure 2b). These results are also consistent with in vitro 
mutagenesis experiments [18]; alanine substitution of residues R49, K51, R52, or R53 slightly weaken 
7DW¶V ELQGLQJ WR WKH%5' [18]. Similarly, the mutation of Y47 and Q54 to alanine hampers PCAF 
BRD binding to the Tat46SYGR(AcK)KRRQRC56 peptide. Most of these HCs are present in the 
Tat46SYGR(AcK)KRRQRC56.PCAF NMR structure [18] (Table 1). Additionally, our model predicts 
interactions between AcK50±K753, AcK50±N798 (Figure 2a) and S46±Y809 (Figure 2b); the last 
predicted interaction is possibly because residues flanking both sides of S46 contribute to the complex 
formation (Figure 2b). In addition, the V763±Y47 contact is present in the NMR structure only and 
absent in our model (Figure 2c). This is due to the fact that the formations of new HCs at the  
N-terminus affect the position of Y47 in the BRU Tat.PCAF model. The new HCs include Tat E2 to 
PCAF E756, A757, P758; P3 to P758; S46 to P804, Y809. As a result, the RMSD of Tat Y47 exhibits 
a difference of 4.8 Å with respect to the full length Tat. 
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Table 1. Effect of mutations in in vitro experiment for Tat46SYGR(AcK)KRRQRC56 (synthesis) complex with p300/(CREB-binding protein)-
associated factor (PCAF) bromodomain (BRD) [18] or in vivo experiment for full-length acetylated Z2 Tat with PCAF BRD [52]. The 
corresponding contacts in both BRU Tat.PCAF docking and molecular dynamics (MD) models presented in this work are reported in the last 
columns (black = agreement; red = new contacts). Coverage in the last column is the percentage of the occurrence of hydrophobic contacts 
(HCs) over all frames in MD simulation.  
Effect on Tat.PCAF 
binding 
Mutants In contact with 
BRU Tat.PCAF model 
(docking) 
BRU Tat.PCAF model (MD) Coverage (%) 
inhibiting binding [18] AcK50A 
F748, V752, Y760, I764 F748, V752, Y760, I764 F748, V752, Y760 100% 
Y802 Y802 Y802 80% 
Y809 Y809 Absent  
 K753, N798 E756, D769, N798, P747 100% 
inhibiting binding [18] 
Y47A V763 Absent Absent  
V763 Y47 
P804, S807 N803 80% 
E808 E808 100% 
 Y809 80% 
Q54A E756 E756 E756 80% 
E756A Q54 R53, Q54 R53, Q54 80% 
strongly diminishing binding 
[18] 
R53E E756 E756, K753, T755 E756, K753, T755 100% 
F748A Tat46SYGR(AcK)KRRQRC56 AcK50 AcK50 100% 
V752A Tat46SYGR(AcK)KRRQRC56 AcK50, R51 AcK50, R51 100% 
Y802A Tat46SYGR(AcK)KRRQRC56 AcK50 AcK50 100% 
Y809A Tat46SYGR(AcK)KRRQRC56 AcK50, S46 S46 100% 
Diminishing binding [18] 
R49A PCAF BRD 
P747, E750 W746, P747, E750, Y802 100% 
 F748 80% 
K51A PCAF BRD 
E750, V752, K753 F748, E750, V752, E756 100% 
 K753 50% 
R52A PCAF BRD 
K753 K753 25% 
E756 E756 100% 
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Table 1. Cont. 
Effect on Tat.PCAF 
binding 
Mutants In contact with 
BRU Tat.PCAF model 
(docking) 
BRU Tat.PCAF model (MD) Coverage (%) 
Diminishing binding [52] 
Y760D AcK50 AcK50 AcK50 100% 
Y761D AcK50 AcK50 Absent  
no effect [18] 
W746A, 
D769A, 
C799A, 
N803A 
  R49 100% 
E750A  R49 R49 100% 
T755A  R53 R53 100% 
I764A  AcK50 AcK50 100% 
N798A  AcK50 AcK50 100% 
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Figure 2. BRU Tat.PCAF BRD interface (a) HCs between R49, AcK50, R51 of BRU Tat 
(green) and PCAF BRD (orange) contacts at the core protein/protein interface are reported. 
Residues at the interaction interface are represented in stick forms; (b) The HCs between 
BRU Tat (green) and PCAF BRD (orange) contacts at the edge protein/protein interface 
are reported. Residues at the interaction interface are represented in stick forms;  
(c) The position of Y47 (shown with balls) and V763 (shown with sticks) represented in the  
complex of BRU Tat.PCAF model were superimposed with the same residues in 
Tat46SYGR(AcK)KRRQRC56.PCAF (black) NMR structure [18] (in green and orange, 
respectively); (d) A schematic view of the HCs between BRU Tat and PCAF BRD. The 
red dotted lines are the HCs newly found in BRU Tat.PCAF model; (e) The new HBs in 
BRU Tat.PCAF model (in green and orange, respectively) with oxygen and nitrogen atoms 
in red and blue, respectively; (f) salt-bridges (SBs) between BRU Tat (green) and PCAF 
(orange) between R53±E756, R49±E750, K51±E750.  
(a) 
 
(b) 
 
  
AcK50
R49
K51
P747
Y760E750
V752
K753
PCAF
Tat
Y809
Y802
N798
F748
I764
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Figure 2. Cont. 
(c) (d) 
  
(e) (f) 
  
A schematic view of the HCs between Tat and PCAF BRD is shown in Figure 2d. 
Tat AcK50 forms HBs with V752, F748, N798, Y802 and Y809. Tat R53 and Tat Q54  
make HBs with PCAF E756 (Figure 2e) (Table 2). These HBs are also present in the 
Tat46SYGR(AcK)KRRQRC56.PCAF NMR structure [18] (Figure 2e) and are consistent with our 
model of Z2 Tat.PCAF [52].  
New HBs between R49 and E750, P747 were found in our model (Table 2) at the interface. In the 
N-terminal of Tat, E2 and P3 make a HB to PCAF P758. 
Finally, the R53±E756, R49±E750, K51±E750 SBs are present (Figure 2f) in the BRU Tat.PCAF 
BRD model. These residues are all at the interface of Tat and PCAF with the high density of 
basic/acidic residues. Only the first SB was present in Tat46SYGR(AcK)KRRQRC56.PCAF NMR 
structure [18]. This SB was also present in our previous model [52].  
The five representative clusters of Tat.PCAF complex from MD simulation are compared with the 
docked model and the NMR structure. The HCs are shown in Table 1. The structures obtained by 
docking and those obtained by MD are not too dissimilar (Tables 1 and 2). In particular, some 
hydrophobic contacts (AcK50±E756, AcK50±D769, Ack50±P747, R49±W746, R49±F748, R49±Y802, 
K51±K753, K51±E756) are present in the MD structures but absent in the docked structures. None of 
the intermolecular HBs with a coverage of more than 50% over the frames is retained in MD. The 
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models generated by data-driven docking and MD show that the hydrophobic interactions may play a 
leading role in Tat.PCAF BDB complex stabilization.  
Table 2. Selected intermolecular hydrogen bonds (HBs) in the BRU Tat.PCAF model by docking. 
Donors Acceptors 
AcK50 V752 
AcK50 F748 
AcK50 Y809 
AcK50 Y802 
N798 AcK50 
R49 * P747 * 
R49 * E750 * 
R53 E756 
R53 K753 
R55 E756 
Q54 E756 
E2 * P758 * 
P3 * P758 * 
* The residues form new HBs in the BRU Tat.PCAF model. 
2.2. Structural Rearrangements of Tat and PCAF upon Binding  
In the Tat46SYGR(AcK)KRRQRC56.PCAF BRD complex [18], the binding interface between Tat 
and PCAF BRD is composed of Tat residues 47±55 and PCAF BRD residues 722±781. The inclusion 
of the complete Tat protein in our model imposes structural constraints that result in conformational 
differences, which, however, do not significantly alter the identity of the contacts.  
The structural changes mostly involve the Tat BRU variant: The RMSD of the backbone  
atoms between the Tat47YGR(AcK)KRRQR55 of our model and the NMR structure of 
Tat46SYGR(AcK)KRRQRC56.PCAF BRD [18] is as large as 4 Å. The RMSD of the 47YGRKKRRQR55 
segment relative to the Tat46SYGR(AcK)KRRQRC56.PCAF BRD NMR complex [18] ranges  
from 2.6 Å to 3.4 Å. A similar result is also found after MD simulations. Indeed, the binding regions 
(Tat47í55 and PCAF722í781 BRD) rearrange 3.1 Å and 2.6 Å, respectively, compared to the same 
residues on NMR structures, while the whole complex shows remarkable changes (RMSD 24.5 Å). 
This indicates that the binding region rearranges less than the rest of the protein.  
Dramatic changes were instead observed in the N-terminal segment on Tat upon binding with the  
P-TEFb complex (see Supplementary Section S5 for more details [17]).  
Notably, the RMSD between the present model (using the BRU variant) with that previously 
reported by us for the Z2 variant [15] (which has 79.1% sequence identity with BRU Tat, see 
Supplementary Figure S1) is as much as 9.5 Å. The main differences involve the N-termini, with a 
RMSD of 17 Å dissimilarity between the two structures, and the C-termini which differ by as much 
as 14 Å; the Tat46SYGR(AcK)KRRQRC56 is more conserved, with 3.3 Å dissimilarity. The AcK50 in 
BRU and Z2 Tat.PCAF BRD model was outside the Tat loop such as K50 in Tat full-length BRU 
variant in unbound conformers. In Z2 Tat full-length, the K50 instead turns inside the loop  
(See Supplementary Figure S1b). We further notice that in spite of their differences in sequence and 
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overall structure (See Supplementary Figure S1b), the N-termini of Z2 and BRU Tat form similar 
contacts with PCAF BRD and residues in the N-terminal extremity of Tat. Different segments for the 
Z2 and BRU variants of Tat are conserved in terms of the intermolecular contacts with PCAF [12], as 
described in Section 2.1. 
The PCAF BRD structure remains close to the protein in the free state in solution: The RMSD of 
the backbone relative to that of the NMR structure [18] is only 0.8 Å (Table 1). 
We further notice that docking of the Tat46SYGR(AcK)KRRQRC56 peptide onto the PCAF BRD 
(see Methods Section and Supplementary Section S3) resulted in structural deviations differing 
by 0.9 Å and 1.3 Å for each of the components and 1.7 Å for the whole complex (Table 3). These 
values are well within the range of variation of RMSD reported for the NMR structure described in 
Table 3. This may suggest that our docking procedure is rather accurate.  
Table 3. Calculated backbone RMSD values between the BRU Tat.PCAF docking and MD 
models and the Tat47YGR(AcK)KRRQR55.PCAF NMR structure (conformer 8 [18], see 
Methods for details). The abbreviations min., max., avg., sd. stand for minimum, 
maximum, average, standard deviation of RMSD values, respectively. 
Systems 
Backbone RMSD 
(Å):PCAF 722±781 
Backbone RMSD (Å): 
Tat47YGR(AcK)KRRQR55 
Backbone RMSD (Å): 
Full complex (same residues) 
min. max. avg. min. max. avg. min. max. avg. 
Tat47YGR(AcK)KRR
QR55.PCAF*(1JM4) 
0.6 1.5 1.0 0.7 1.2 2.3 0.9 1.9 1.33 
sd. 0.2 sd. 0.5 sd. 0.26 
Tat47YGR(AcK) 
KRRQR55.PCAF 
(Prediction) 
1.3 0.9 1.7 
BRU Tat.PCAF 
(Prediction by 
docking) 
0.8 4.0 14.4 
BRU Tat.PCAF 
(Prediction by  
MD simulation,  
the last frame) 
2.9 3.3 3.1 
sd. 0.2 
2.8 3.4 2.6 
sd. 0.4 
24.7 25.8 24.5 
sd. 1.2 
2.3. Key Residues of PCAF BRD for Its Interaction with Tat 
The sequence and structure conservation of Tat has been discussed by us in [12]. Here we focus on 
residues of PCAF human BRD important for Tat binding (See multiple sequence alignment of PCAF 
human BRD in Supplementary Figure S2). There are 53 PCAF human bromodomain (BRD) sequences 
as obtained from bromodomain PROSITE family, accession number PS50014 [59±61]. We start our 
discussion by listing the most conserved residues of this protein family (Table 4). In particular, P758, 
which makes HBs with E2 and P3 of Tat, is highly conserved among PCAF BRD sequences 
(71% identity, Table 4) and P747 (identity 53% respect to PCAF BRD sequences, Table 4 and 
Supplementary Figure S2). Notably, the N798, which makes an HB with AcK50, is one of the most 
conserved residues in PCAF BRD (96%, Table 4). P747 and N798 residues, which are involved in 
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several HCs and HBs (Tables 1 and 2 and Supplementary Tables S3 and S4), seem to play an 
important role for the Tat.PCAF interaction. Moreover, due to the overall structure similarities of 
PCAF BRD [62], the N798 may play an important role in the interaction of PCAF BRD with other 
cellular partners [63].  
Table 4. Conserved residues of the existing 53 PCAF human bromodomain (BRD) 
sequences as obtained from the bromodomain PROSITE family, accession number 
PS50014 [59±61]. 
Residues Identity (%) Residues Identity (%) 
P747 53% T772 69% 
F748 91% Y782 97% 
P751 68% F788 63% 
V752 71% D791 89% 
P758 71% F796 60% 
I764 76% N798 96% 
P767 97% Y802 77% 
D769 85% N803 88% 
L770 66%   
3. Computational Methods Section 
The structure of HIV-1 Tat (86 residues) has been solved by NMR (PDBID 1JFW [13]). Eleven 
conformers have been deposited. His13, His33, His65 are protonated in the 1İ [13]. We superimposed 
residues 47 to 55 in each of these structures with the corresponding ones with the multiple conformers 
of Tat46SYGR(AcK)KRRQRC56 peptide in complex with human PCAF BRD, whose structure has 
been solved by NMR. His717 and His742 were protonated in 1į as in the NMR structure (1JM4 [18]).  
The VMD 1.8 program [64] was used. The conformer n.8 of HIV-1 Tat and n.3 of the 
Tat46SYGR(AcK)KRRQRC56.PCAF complex exhibits the lowest pairwise root-mean-square deviation 
(RMSD) in respect Tat46SYGR(AcK)KRRQRC56 backbone (2.3 Å and 0.7 Å, respectively). All the 
RMSDs reported in this paper are calculated using only backbone atoms. Thus, these conformers were 
selected for all subsequent calculations. The full length Tat was fitted to Tat46SYGR(AcK)KRRQRC56 
at the peptide then AcK50 was replaced with K50 in full length Tat using the tleap module in AMBER 
package [65] with acetylated lysine parameters adapted from Machado et al. [66]. The resulting 
structure was relaxed for 10 ns molecular dynamics simulation in water (See Supplementary 
Section S1; RMSF, RMSD of the system plotted as a function of simulated time in Supplementary 
Figure S3 and Figure S4 for further details). A clustering of the MD trajectory [67] identified seven 
clusters, 84 structures in total, which represented 98% of the conformations (Supplementary 
Section S2). These structures were docked on the 25 PCAF BRD conformers present in the NMR 
family of structures (1JM4 [18]) by a multiple conformations docking procedure using the HADDOCK 
2.1 program [53,54,68]. Haddock is an information-driven flexible docking approach for the modeling 
of biomolecular complexes [40]. The entire protocol consists of four stages: (i) Topology and structure 
generation; (ii) Randomization of the starting orientation and rigid body energy minimization; 
(iii) Semi-flexible simulated annealing; (iv) Flexible refinement in explicit solvent (water). 
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We first validated our docking procedure by redocking the Tat46SYGR(AcK)KRRQRC56 from 
PCAF BRD in the NMR structure of the complex (Supplementary Section S3) [18]. Then, the two 
binding partners were docked one onto the other by rigid body docking with different Ambiguous 
Interaction Restraints (AIRs) (Supplementary Section S3, Table S2, for the definition of AIRs, see [54]). 
The adduct exhibited a backbone RMSD of 1.3 Å for PCAF BRD and 1.7 Å for HIV-1 
Tat46SYGR(AcK)KRRQRC56 with respect to the NMR structure (Supplementary Section S3, Figure S4) 
(Table 3). These results allow us to suggest that HADDOCK performs well for this system 
(Supplementary Section S3). Next, we performed rigid-body docking between PCAF BRD and 
Tat AcK50. The contacts F748±, V752±, Y809±, I764±, Y760±, Y802± to AcK50, E756± to R53, 
V763± to Y47, E756± to Q54, present in the NMR structure [18], were treated as AIRs. The rigid-body 
docking was followed by a rigid body energy minimization, a semi-flexible simulated annealing in 
torsion angle space and a refinement by MD at a temperature of 300K in explicit solvent [54,69]. Next 
we selected the 500 top structures in terms of the highest docking score and the lowest RMSD relative 
to the NMR structure [18]. In these 500 structures, a short MD simulation was performed to optimize 
the water positions while proteins were fixed (4,000 steps of MD consisting four times 1,000 steps at a 
temperature of 600, 500, 400 and 300 K, respectively [69]. This was followed by MD at 300K in 
water [54]. A clusterization procedure was performed with a cut-off at 3.0 Å from the final 500 structures 
(94% structures were clusterized). We finally selected the structure that had the lowest RMSD (0.8 Å 
for PCAF and 4 Å for Tat), which is representative for the most crowded cluster. This is the structure 
discussed in the Results and Discussion Section. Other representative structures are discussed in 
Supplementary Table S3. 
The representative of the Tat.PCAF model from docking underwent MD simulations in explicit 
water. Tat.PCAF BRD was solvated in 104 × 70 × 66 Å3 box, containing 39.363 water molecules,  
16 chlorine ions were added to neutralize the total charge of the system. The AMBER force field 
ff99SB [70] was used for the protein and the chlorine atoms; the TIP3P model [71] was used for water. 
The acetylated lysine topology parameter was taken from Machado et al. [66].  
Periodic boundary conditions were used and a cutoff of 12 Å [72] was adopted for short-range  
non-bonded interactions. The particle mesh Ewald summation method [73] was used for long-range 
electrostatic interactions. A dielectric constant of one was assumed. All chemical bonds were 
constrained by using the SHAKE algorithm [74]. The equations of motion were integrated using a time 
step of 2 fs. Temperature and pressure were kept constant at 300 K and 1 atm by coupling the system 
to external baths [75] with a Langevin thermostat (coupling constants st = 0.05) and a Berendsen 
barostat (coupling constants sp = 0.5 ps), respectively. 
After 5,000 steps of minimization (steepest descent algorithm for the first 1,500 steps before 
switching to the conjugate gradient algorithm for the remaining 3,500 steps), the system was 
equilibrated for 300 ps. Eighty nanoseconds of MD simulation were performed at 300 K and 2 ps for 
the time steps. We clusterized [67] the trajectory into five clusters. The backbone RMSD of the 
Tat.PCAF BRD structures over 80 ns is shown in Supplementary Figure S7. NAMD package was used 
for MD simulation [76]. 
Hydrophobic contacts at the protein/protein contact surface were defined as two non-polar carbon 
atoms at a distance of 4.0 Å or less. Hydrogen bonds were defined as a polar hydrogen at a distance 
of 2.5 Å or less from a polar atom (nitrogen or oxygen). Salt bridges were considered formed if the 
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distance between any of the oxygen atoms of acidic residues and the nitrogen atoms of basic residues 
were less than 4.0 Å. Coverage was defined as the percentage of the occurrence of HCs over all frames 
in MD simulation or all representative structures in docking. The HADDOCK [53,54], LIGPLOT [77] 
and VMD [64] programs were used to calculate these quantities. 
4. Conclusions 
We have presented a model of the BRU Tat.PCAF complex produced by data-driven docking 
combined with MD simulations, which may add structural information to the intricate mechanism of 
Tat transcription and trans-activation, up to now not fully understood [10,11]. The structures obtained 
by docking and those obtained by MD are similar in the binding region. This model was obtained  
with a more accurate procedure than that used in [52] and it focuses on the more common BRU  
variant rather than the Z2 strain of HIV-1. The two models show conservation as far as the 
Tat46SYGR(AcK)KRRQRC56 and N-terminal contacts with PCAF BRD are concerned. In addition, the 
model suggests the presence, only for the Z2 strain of Tat, of hydrophobic contacts and hydrogen 
bonds between Tat and PCAF that are not present in the previous model of Z2 Tat.PCAF [52]. 
Specifically, the BRU Tat.PCAF model differs from the Z2 Tat.PCAF complex on HBs between R49 
and P747, E750, between P758 and E2, P3 and on HCs between S46 and P804, Y809. 
The model appears to be consistent with most of the experimental data obtained with 
Tat46SYGR(AcK)KRRQRC56.PCAF in vitro [18] (synthesized Tat peptide) and full length Tat.PCAF 
in vivo [52]. However, this comparison has to be interpreted with caution because of the assumption 
that most of the intermolecular interactions compared here do not vary when passing from the in vitro 
to the in vivo situation and/or from the Tat46SYGR(AcK)KRRQRC56 to the full length protein.  
Several BRD amino acids have been identified as crucial for Tat binding (E750, V752, E756, A757, 
Y802, Y809) and as the targets for development of small molecules blocking Tat.PCAF association [78,79]. 
Our model allows us to suggest that the hydrophobic interactions seem to be a crucial factor for BRD 
binding to Tat.  
Further, our model allows us to suggest that N798 in the BRD plays a key role for Tat binding, 
independently of whether this protein is expressed by the BRU or the ZZ variant of HIV-1. Indeed, this 
residue creates a HB with AcK50 in the X-ray structure of Tat and other cellular partners [41,42,49], in 
both the Z2 Tat.PCAF model [52] and in our model. Hence, interfering with N798-AcK50 interactions 
may be a valuable strategy for drug design [63,80]. Because this residue is highly conserved 
(Supplementary Figure S3 and Table 4), it may form key interactions also with other BRD cellular 
partners [18,31,32,62,81]. Moreover, some studies showed that specific small molecules binding at the 
acetylated lysine recognition pocket can antagonize the bromodomains and acetylate histone interactions, 
especially the HB between asparagine in ĮB loop and acetylated lysine [30,80,82±89]. Therefore, 
designing compounds, which bind to N798 may also lead to other potential therapeutic applications. 
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